Press Release

Printer Friendly Version View printer-friendly version
« Back
FibroGen to Participate in Upcoming Investor Conferences

SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences:

Bank of America Health Care Conference 
Format: 1x1 investor meetings
Date: Tuesday, May 14, 2024
Location: Las Vegas, NV

H.C. Wainwright 2nd Annual Bioconnect Investor Conference 
Format: Fireside Chat and 1x1 investor meetings
Date: Monday, May 20, 2024
Fireside Chat Time: 1:30 PM ET
Location: New York, NY

The live audio webcast of the H.C. Wainwright Fireside Chat will be available to investors and other interested parties on the “Events & Presentations” section of the FibroGen Investor webpage at A replay will be available for 30 days.

About FibroGen 
FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, a fully human anti-CTGF monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC). Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of an associated CD46-targeted PET biomarker. In addition, FibroGen has expanded its research and development portfolio to include two immuno-oncology product candidates for the treatment of solid tumors. For more information, please visit

FibroGen, Inc.

David DeLucia, CFA
Vice President of Corporate FP&A / Investor Relations

Meichiel Keenan
Director, Investor Relations and Corporate Communications


Primary Logo

Source: FibroGen, Inc.